N/A
N=10
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Pre-diabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Bottom Line
View on ClinicalTrials.gov: NCT01488279 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2018
Primary outcome: Primary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Dexamethasone 2.5 mg and Sitagliptin 100 mg (Drug); Dexamethasone 2.5 mg and placebo tablet (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Vermont
- Primary completion
- Jul 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin Sensitivity |
1835.4; 1846.0 | .983 |
| SECONDARY Change in Active GIP |
— | — |
| SECONDARY Change in Active GLP-1 |
— | — |
| SECONDARY Change in Glucose Response |
4.219; 4.228 | .997 |
| SECONDARY Change in Insulin Secretion (AIRg or Acute Insulinogenic Response to Glucose) |
519.6; 558.6 | .460 |
Summary
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
Eligibility Criteria
Inclusion Criteria
- Men and women
- impaired fasting glucose
- We will stratify for weight and age.
Exclusion Criteria
- Known Type 2 DM
- Severe disease preventing participation in study
- On chronic steroids for any reason
- Already taking DPP-4 inhibitor
Data sourced from ClinicalTrials.gov (NCT01488279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.